These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 2883132)
1. Effect of a new selective H1 receptor antagonist (levocabastine) in a nasal and conjunctival provocation test. Pécoud A; Zuber P; Kolly M Int Arch Allergy Appl Immunol; 1987; 82(3-4):541-3. PubMed ID: 2883132 [TBL] [Abstract][Full Text] [Related]
2. Levocabastine: a new topical approach for the treatment of paediatric allergic rhinoconjunctivitis. Janssens MM Rhinol Suppl; 1992 Sep; 13():39-49. PubMed ID: 1358140 [TBL] [Abstract][Full Text] [Related]
3. Comparison of levocabastine, a new selective H1-receptor antagonist, and disodium cromoglycate, in a nasal provocation test with allergen. Kolly M; Pécoud A Br J Clin Pharmacol; 1986 Oct; 22(4):389-94. PubMed ID: 2876723 [TBL] [Abstract][Full Text] [Related]
4. Comparison of effects of topical levocabastine and nedocromil sodium on the early response in a conjunctival provocation test with allergen. Hammann C; Kämmerer R; Gerber M; Spertini F J Allergy Clin Immunol; 1996 Dec; 98(6 Pt 1):1045-50. PubMed ID: 8977503 [TBL] [Abstract][Full Text] [Related]
5. Topical levocabastine, a selective H1 antagonist, in seasonal allergic rhinoconjunctivitis. Bende M; Pipkorn U Allergy; 1987 Oct; 42(7):512-5. PubMed ID: 2891316 [TBL] [Abstract][Full Text] [Related]
6. Effects of topical treatment with H1 and H2 antagonists on clinical symptoms and nasal vascular reactions in patients with allergic rhinitis. Holmberg K; Pipkorn U; Bake B; Blychert LO Allergy; 1989 May; 44(4):281-7. PubMed ID: 2567579 [TBL] [Abstract][Full Text] [Related]
7. Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. Noble S; McTavish D Drugs; 1995 Dec; 50(6):1032-49. PubMed ID: 8612470 [TBL] [Abstract][Full Text] [Related]
8. Levocabastine: an effective topical treatment of allergic rhinoconjunctivitis. Janssens MM; Vanden Bussche G Clin Exp Allergy; 1991 May; 21 Suppl 2():29-36. PubMed ID: 1680536 [TBL] [Abstract][Full Text] [Related]
9. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model. Netland PA; Leahy C; Krenzer KL Am J Ophthalmol; 2000 Dec; 130(6):717-23. PubMed ID: 11124289 [TBL] [Abstract][Full Text] [Related]
10. The effect of levocabastine nasal spray in nasal provocation tests. Palma-Carlos AG; Palma-Carlos ML; Rombaut N Int J Clin Pharmacol Res; 1988; 8(1):25-30. PubMed ID: 2896636 [TBL] [Abstract][Full Text] [Related]
11. Topical levocabastine protects better than sodium cromoglycate and placebo in conjunctival provocation tests. Rimås M; Kjellman NI; Blychert LO; Björkstén B Allergy; 1990 Jan; 45(1):18-21. PubMed ID: 1968726 [TBL] [Abstract][Full Text] [Related]
12. Effect of levocabastine, a new H1 antagonist, in a conjunctival provocation test with allergens. Zuber P; Pécoud A J Allergy Clin Immunol; 1988 Oct; 82(4):590-4. PubMed ID: 2902114 [TBL] [Abstract][Full Text] [Related]
13. Eosinophil cationic protein (ECP) and tryptase in the nasal lavage fluid (NLF) of children with grass pollen rhinitis: levocabastine effect. Bernardini R; Novembre E; Mugnaini L; Rossi ME; Vierucci A Allergy Asthma Proc; 1998; 19(2):75-80. PubMed ID: 9578915 [TBL] [Abstract][Full Text] [Related]
14. Effects of topical budesonide and levocabastine on nasal symptoms and plasma exudation responses in seasonal allergic rhinitis. Svensson C; Andersson M; Greiff L; Blychert LO; Persson CG Allergy; 1998 Apr; 53(4):367-74. PubMed ID: 9574878 [TBL] [Abstract][Full Text] [Related]
15. Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Dechant KL; Goa KL Drugs; 1991 Feb; 41(2):202-24. PubMed ID: 1709851 [TBL] [Abstract][Full Text] [Related]
16. Topical levocabastine compared with orally administered terfenadine for the prophylaxis and treatment of seasonal rhinoconjunctivitis. Søhoel P; Freng BA; Kramer J; Poppe S; Rebo R; Korsrud FR; Garud O; Woxen OJ; Olsen AK J Allergy Clin Immunol; 1993 Jul; 92(1 Pt 1):73-81. PubMed ID: 8101534 [TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model. Abelson MB; Greiner JV Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212 [TBL] [Abstract][Full Text] [Related]
18. Intranasal levocabastine provides fast and effective protection from nasal allergen challenge. Bachert C; Wagenmann M; Vossen-Holzenkamp S Rhinology; 1996 Sep; 34(3):140-3. PubMed ID: 8938880 [TBL] [Abstract][Full Text] [Related]
19. A double-blind, placebo-controlled comparison of treatment with fluticasone propionate and levocabastine in patients with seasonal allergic rhinitis. FLNCO2 Italian Study Group. Ortolani C; Foresi A; Di Lorenzo G; Bagnato G; Bonifazi F; Crimi N; Emmi L; Prandini M; Senna GE; Tursi A; Mirone C; Leone C; Fina P; Testi R Allergy; 1999 Nov; 54(11):1173-80. PubMed ID: 10604553 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of levocabastine in conjunctival provocation studies. Janssens M Doc Ophthalmol; 1992; 82(4):341-51. PubMed ID: 1363980 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]